Becton Dickinson — May 1, 2025 release

Page 13 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2025 OUTLOOK RECONCILIATION Full Year FY 2024 Full Year FY 2025 Outlook ($ in millions) % Change Revenues BDX Reported Revenues $ 20,178  Add: Revenue Adjustment Impact 67  Adjusted Revenues $ 20,245  FY 2025 Reported Revenue Growth +8.0% to +8.5% Revenue Adjustment Impact ~+35 basis points Illustrative Foreign Currency (FX) Impact (~10) basis points FY 2025 Revenue Growth (adjusted) (FXN) +7.8% to 8.3% FY 2025 Inorganic Impact to Revenue Growth ~+475 basis points FY 2025 Organic Revenue Growth (FXN) +3.0% to +3.5% Total FY 2025 Revenues ~$21.8 to $21.9 billion Notes - Revenue Adjustment Impact reflects the recognition of accruals resulting from developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024. - Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Page 14 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2025 OUTLOOK RECONCILIATION CONTINUED Full Year FY 2025 Outlook Full Year FY 2024 from Continuing Operations Total Company Reported Diluted Earnings per Share $ 5.86  Purchase accounting adjustments ($1.503 billion pre-tax) (1) 5.16  Integration costs ($23 million pre-tax) (2) 0.08  Restructuring costs ($387 million pre-tax) (2) 1.33  Transaction Costs ($48 million pre-tax) (3) 0.17  Financing Costs (($8) million pre-tax) (3) (0.03) Separation-related items ($13 million pre-tax)